$1.21
6.14% yesterday
Nasdaq, May 12, 10:09 pm CET
ISIN
US18978H1023
Symbol
CNSP
Sector
Industry

Cns Pharmaceuticals Inc Stock price

$1.21
-0.07 5.47% 1M
-5.17 81.02% 6M
-4.81 79.90% YTD
-508.79 99.76% 1Y
-20,586.29 99.99% 3Y
-206,998.79 100.00% 5Y
-342,748.79 100.00% 10Y
Nasdaq, Closing price Mon, May 12 2025
+0.07 6.14%
ISIN
US18978H1023
Symbol
CNSP
Sector
Industry

Key metrics

Market capitalization $3.56m
Enterprise Value $-2.57m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.15
P/B ratio (TTM) P/B ratio 0.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.90m
Free Cash Flow (TTM) Free Cash Flow $-17.12m
Cash position $6.46m
EPS (TTM) EPS $-1,367.97
P/E forward negative
Short interest 11.00%
Show more

Is Cns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Cns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cns Pharmaceuticals Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Cns Pharmaceuticals Inc:

Hold
100%

Financial data from Cns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.61 5.61
18% 18%
-
- Research and Development Expense 9.29 9.29
34% 34%
-
-15 -15
21% 21%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
21% 21%
-
Net Profit -15 -15
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cns Pharmaceuticals Inc Stock News

Neutral
Accesswire
36 minutes ago
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Management releases "What This Means" segment discussing the receipt of Orphan Drug Designations for TPI 287; Access here HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ...
Neutral
Accesswire
about one month ago
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for treatment of brain malignancies HOUSTON, TX / ACCESS Newswire / April 1, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a b...
Neutral
Accesswire
about 2 months ago
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity.
More Cns Pharmaceuticals Inc News

Company Profile

CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.

Head office United States
CEO John Climaco
Employees 5
Founded 2017
Website www.cnspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today